Download pdf
On-target off-tumor toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions
- 1 School of Interdisciplinary Science, McMaster University, ON, Canada
* Author to whom correspondence should be addressed.
Abstract
One of the biggest threats to women’s lives and health is breast cancer, with HER2+ breast cancer accounting for a significant proportion of cases. This subtype is characterized by aggressive behavior, a high recurrence rate, and generally poor prognosis. While traditional HER2-CAR-T cell therapy has proven to show great success in treating HER2+ breast cancer, it carries the risk of on-target off-tumor toxicity, which could be life-threatening for patients. This review outlines the challenges associated with traditional HER2-CAR-T cell therapy and explores current strategies aimed at mitigating on-target off-tumor toxicity. The review categorizes these strategies into three main approaches, providing a comprehensive overview to help the medical and research community better understand the current state and future directions of HER2-CAR-T cell therapy. By discussing these approaches and the underlying mechanisms that make them effective, this review aims to inspire further innovation in improving existing HER2-CAR-T cell therapies. A thorough understanding of the current challenges and promising avenues for enhancement in HER2-CAR-T cell therapy is essential for advancing future research and clinical applications.
Keywords
HER2, CAR-T cells, on-target off-tumor toxicity, multi-antigen targeting, SynNotch
[1]. World Health Organization. (2024). https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
[2]. Amjad, M. (2023). Cancer chemotherapy. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK564367/
[3]. Bayer V. (2019). An Overview of Monoclonal Antibodies. Seminars in oncology nursing, 35(5), 150927. https://doi.org/10.1016/j.soncn.2019.08.006
[4]. Shastry, M., Gupta, A., Chandarlapaty, S., Young, M., Powles, T., & Hamilton, E. (2023). Rise of antibody-drug conjugates: The present and future. American Society of Clinical Oncology Educational Book. https://ascopubs.org/doi/10.1200/EDBK_390094
[5]. Barok, M., Joensuu, H., & Isola, J. (2014). Trastuzumab emtansine: mechanisms of action and drug resistance. Breast cancer research : BCR, 16(2), 209. https://doi.org/10.1186/bcr3621
[6]. Goodman, A. (2024). Long-term follow-up supports postneoadjuvant T-DM1 over trastuzumab in early, high-risk, HER2-positive breast cancer. The ASCO Post. https://ascopost.com/issues/january-25-2024/long-term-follow-up-supports-postneoadjuvant-t-dm1-over-trastuzumab-in-early-high-risk-her2-positive-breast-cancer/#:~:text=The%20absolute%20invasive%20disease%E2%80%93free, 0001
[7]. Peddi, P. F., & Hurvitz, S. A. (2014). Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 202–209. https://doi.org/10.1177/1758834014539183
[8]. Malik, B. (2023). Understanding how monoclonal antibodies work. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK572118/
[9]. Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy, 11(2), 263–275. https://doi.org/10.1586/era.10.226
[10]. Gu, Y., Wang, Z., & Wang, Y. (2024). Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica B, 14(5), 1965–1986. https://doi.org/10.1016/j.apsb.2024.01.009
[11]. Hunter, F. W., Barker, H. R., Lipert, B., Rothé, F., Gebhart, G., Piccart-Gebhart, M. J., Sotiriou, C., & Jamieson, S. M. F. (2020). Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British journal of cancer, 122(5), 603–612. https://doi.org/10.1038/s41416-019-0635-y
[12]. van de Donk, N. W., & Dhimolea, E. (2012). Brentuximab vedotin. mAbs, 4(4), 458–465. https://doi.org/10.4161/mabs.20230
[13]. Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S. P., Shustov, A., … ECHELON-2 Study Group (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England), 393(10168), 229–240. https://doi.org/10.1016/S0140-6736(18)32984-2
[14]. Horwitz, S., O'Connor, O. A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S. P., Shustov, A., … Illidge, T. (2022). The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 33(3), 288–298. https://doi.org/10.1016/j.annonc.2021.12.002
[15]. Tsuchikama, K., & An, Z. (2018). Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & cell, 9(1), 33–46. https://doi.org/10.1007/s13238-016-0323-0
[16]. Lysine based conjugation. Creative Biolabs. https://www.creative-biolabs.com/adc/lysine-based-conjugation.htm
[17]. Mahesh, S., Tang, K. C., & Raj, M. (2018). Amide Bond Activation of Biological Molecules. Molecules (Basel, Switzerland), 23(10), 2615. https://doi.org/10.3390/molecules23102615
[18]. You, J., Zhang, J., Wang, J., & Jin, M. (2021). Cysteine-based coupling: Challenges and solutions. ACS Publications. https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00213
[19]. Enzymatic conjugation. BOC Sciences. https://www.bocsci.com/enzymatic-conjugation.html#:~:text=Enzymatic%20conjugation%20involves%20modification%20of, found%20in%20the%20tumor%20microenvironment
[20]. Chekalin, E., Paithankar, S., Shankar, R., Xing, J., Xu, W., & Chen, B. (2024). Computational discovery of co-expressed antigens as dual targeting candidates for cancer therapy through bulk, single-cell, and spatial transcriptomics. OUP Academic. https://academic.oup.com/bioinformaticsadvances/article/4/1/vbae096/7696853#469502195
[21]. Shim H. (2020). Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules, 10(3), 360. https://doi.org/10.3390/biom10030360
[22]. Harding, J. J., Fan, J., Oh, D. Y., Choi, H. J., Kim, J. W., Chang, H. M., Bao, L., Sun, H. C., Macarulla, T., Xie, F., Metges, J. P., Ying, J., Bridgewater, J., Lee, M. A., Tejani, M. A., Chen, E. Y., Kim, D. U., Wasan, H., Ducreux, M., Bao, Y., … HERIZON-BTC-01 study group (2023). Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet. Oncology, 24(7), 772–782. https://doi.org/10.1016/S1470-2045(23)00242-5
[23]. Zymeworks Inc. (2022). New clinical data for Zanidatamab in her2+ /hr+ metastatic breast cancer presented today at 2022 SABCS. https://ir.zymeworks.com/news-releases/news-release-details/new-clinical-data-zanidatamab-her2-hr-metastatic-breast-cancer-0
[24]. Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15(3), 713. https://doi.org/10.3390/cancers15030713
[25]. Sheyi, R., de la Torre, B. G., & Albericio, F. (2022). Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics, 14(2), 396. https://doi.org/10.3390/pharmaceutics14020396
[26]. Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Vleet, T. R. V. (2019). Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacology & Therapeutics, 200, 110–125. https://doi.org/10.1016/j.pharmthera.2019.04.008
[27]. Fan, S., He, L., & Sang, D. (2023). Combination therapy with antibody drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD 1 inhibitor) successfully controlled recurrent HER2 positive breast cancer resistant to trastuzumab emtansine: A case report. Oncology letters, 26(2), 359. https://doi.org/10.3892/ol.2023.13945
Cite this article
Wang,Z. (2025). On-target off-tumor toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions. Theoretical and Natural Science,77,107-115.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).